You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2018

Practical Law Life Sciences Global Guide: Pharmaceutical IP and Competition Law in Thailand

Subscribe to Updates
Practical Law

The 2018 edition of Thomson Reuters’ Practical Law Life Sciences Global Guide  has been released, with a chapter on Pharmaceutical Intellectual Property and Competition Law in Thailand penned by legal practitioners from Tilleke & Gibbins.

The guide is a Q&A-style overview of the regulatory frameworks of the life sciences industries across multiple jurisdictions worldwide, with this chapter addressing the following issues as they relate to Thailand:

  • Pharmaceutical patent legislation and scope of protection
  • Patent application process, duration of protection, and revocation
  • Patent infringement, claims, and remedies
  • Non-patent barriers to competition for pharmaceutical protection
  • Pharmaceutical trademark legislation and scope of protection
  • Trademark application process, duration of protection, and revocation
  • Trademark infringement, claims, and remedies
  • Regulatory powers and enforcement against pharmaceutical counterfeiting
  • Competition law framework and implications for the pharmaceutical sector
  • Competition issues related to licensing of pharmaceutical technology and patents, and market entry of generic products
  • Market dominance issues in the pharmaceutical sector
  • Parallel imports
  • Foreign patent and trademark licenses, and payment of royalties

Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. Tilleke & Gibbins also drafted a chapter on Medicinal Product Regulation and Product Liability in Thailand for the 2018 edition of the guide.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Antitrust and Competition

Customs and International Trade

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

April 19, 2021
Thailand has made significant changes to its statutory interest rate framework for the first time in almost a century. Since 1925, the statutory interest rate codified in Thailand’s Civil and Commercial Code (the CCC) has remained at 7.5% per year. But with Covid-19 having an unprecedented impact on the Thai economy, the Thai Government, via emergency decree, has reduced the statutory rate. While the decree is largely aimed at providing relief to hard-hit SMEs and individual debtors, the amendments have broader implications for doing business in Thailand. Main Changes The new interest rate revisions are contained within the Emergency Decree Amending the Civil and Commercial Code B.E. 2564 (2021) (the Emergency Decree), which was published in the Government Gazette on April 10, 2021 and came into effect on April 11, 2021. The Emergency Decree amends Sections 7 and 224 of the CCC, which stated the previous statutory interest rate of 7.5% per year. The Emergency Decree makes three major changes. The first involves a reduction of the statutory interest rate from 7.5% per year to 3% per year in Section 7. The new 3% annual rate is subject to review every three years by the Ministry of Finance. The interest rate is subject to further change later by a royal decree. The second change concerns money debts under Section 224 of the CCC. The previous version of Section 224 stated, among other things, that a money debt based on a default bears interest of 7.5% per year. Under the Emergency Decree, the new actual statutory default interest rate is the statutory interest rate stated in Section 7 with an additional rate of 2% per year. The result is a 5% annual statutory default interest rate. Since the statutory default interest rate is based in part on the Section 7
Read More